Abstract
Microvascular vaso-occlusion driven pain crisis is the hallmark of sickle cell disease with profound morbidity and increased mortality. Selectins, most notably P-selectins have an integral role in this phenomenon. P-selection was first identified in 1989. In 2019, after 3 decades of basic, translational, and clinical work with this pathway, the US Food and Drug Administration approved a P-selectin antibody, crizanlizumab to reduce frequency of pain crisis in patients more than 16 years with sickle cell disease. We review the funda-mentals of P-selectin pathobiology, P-selectin blocking agents, clinical data with the use of crizanlizumab and prospects of this novel class of drugs in the context of other treatments for painful vaso-occlusive episodes.
Original language | English (US) |
---|---|
Pages (from-to) | 849-856 |
Number of pages | 8 |
Journal | Journal of Pain Research |
Volume | 14 |
DOIs | |
State | Published - 2021 |
Keywords
- Crizanlizumab
- P-selectin
- Pain crisis
- Sickle cell disease
ASJC Scopus subject areas
- Anesthesiology and Pain Medicine